Christina A. Koscianski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Christina A. Koscianski has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Robin Patel
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic
5 shared publications - Melissa J. Karau
Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
2 shared publications - Akhilesh Pandey
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
1 shared publication - Andrew D. Badley
Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA
1 shared publication Andrey A. Filippov
Wound Infections Department, Bacterial Diseases Branch, Center for Infectious Disease Research, Walter Reed Army Institute of Research
1 shared publication- Daria Van Tyne
Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine
1 shared publication
Latest Publications
- Open Access
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (11)
Comparative plaque- and liquid-based phage susceptibility testing of Pseudomonas aeruginosa isolates in a cystic fibrosis randomized clinical trial
The optimal phage susceptibility testing (PST) method is unclear. Here, two PST methods were compared using Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis enrolled in a placebo-controlled clinical trial of a single intravenous dose of a four-phage cocktail (WRAIR-PAM-CF1). In total, 508 P. aeruginosa sputum isolates were evaluated, including isolates collected before or after phage or placebo treatment, isolates from the same trial participants over time, and isolates of different colony morphologies from the same participants at the same time point. Susceptibility to phages PaWRA01Φ11, PaWRA01Φ39, PaWRA02Φ83, and PaWRA02Φ87 and a cocktail of all four phages was assessed using a plaque assay (PA) and a Biolog Omnilog-based liquid assay (LA) with the same bacterial inoculum. A total of 170/508 isolates (33%) and 195/508 isolates (38%) were identified as susceptible to the cocktail by PA and LA, respectively. Among the susceptible isolates, 169/170 (99%; PA) and 187/195 (96%; LA) also tested susceptible to at least one of the four phages in the cocktail. Susceptible percent agreement between the PA and LA ranged from 76% to 100% and non-susceptible percent agreement ranged from 89% to 100% for all phages studied and the cocktail. Phage PaWRA02Φ83 demonstrated the greatest individual activity, with 164/508 (32%) and 188/508 (37%) isolates testing susceptible by PA and LA, respectively. The four-phage cocktail provided numerically broader coverage of P. aeruginosa (i.e., had the highest susceptibility rate) than did any single phage. There was high concordance between PST results by PA and LA. IMPORTANCE: Standardization of phage susceptibility testing (PST) methods is essential to support phage therapy trials and any future clinical implementation. There are no standardized PST methods or interpretive criteria for PST. In this study, PST was performed by a plaque assay and a Biolog Omnilog-based liquid assay on Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients enrolled in a clinical trial. Susceptibility of 508 isolates to four phages and a cocktail of all four was evaluated. There was high concordance between susceptibility assessed by plaque and liquid assays and numerically broader coverage of P. aeruginosa by the cocktail compared to any single phage. This manuscript should be of interest to those performing PST.
- 11 November 2026
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 64 (11)
Open AccessComparative plaque- and liquid-based phage susceptibility testing of Pseudomonas aeruginosa isolates in a cystic fibrosis randomized clinical trial
The optimal phage susceptibility testing (PST) method is unclear. Here, two PST methods were compared using Pseudomonas aeruginosa isolates recovered from patients with cystic fibrosis enrolled in a placebo-controlled clinical trial of a single intravenous dose of a four-phage cocktail (WRAIR-PAM-CF1). In total, 508 P. aeruginosa sputum isolates were evaluated, including isolates collected before or after phage or placebo treatment, isolates from the same trial participants over time, and isolates of different colony morphologies from the same participants at the same time point. Susceptibility to phages PaWRA01Φ11, PaWRA01Φ39, PaWRA02Φ83, and PaWRA02Φ87 and a cocktail of all four phages was assessed using a plaque assay (PA) and a Biolog Omnilog-based liquid assay (LA) with the same bacterial inoculum. A total of 170/508 isolates (33%) and 195/508 isolates (38%) were identified as susceptible to the cocktail by PA and LA, respectively. Among the susceptible isolates, 169/170 (99%; PA) and 187/195 (96%; LA) also tested susceptible to at least one of the four phages in the cocktail. Susceptible percent agreement between the PA and LA ranged from 76% to 100% and non-susceptible percent agreement ranged from 89% to 100% for all phages studied and the cocktail. Phage PaWRA02Φ83 demonstrated the greatest individual activity, with 164/508 (32%) and 188/508 (37%) isolates testing susceptible by PA and LA, respectively. The four-phage cocktail provided numerically broader coverage of P. aeruginosa (i.e., had the highest susceptibility rate) than did any single phage. There was high concordance between PST results by PA and LA. IMPORTANCE: Standardization of phage susceptibility testing (PST) methods is essential to support phage therapy trials and any future clinical implementation. There are no standardized PST methods or interpretive criteria for PST. In this study, PST was performed by a plaque assay and a Biolog Omnilog-based liquid assay on Pseudomonas aeruginosa isolates recovered from cystic fibrosis patients enrolled in a clinical trial. Susceptibility of 508 isolates to four phages and a cocktail of all four was evaluated. There was high concordance between susceptibility assessed by plaque and liquid assays and numerically broader coverage of P. aeruginosa by the cocktail compared to any single phage. This manuscript should be of interest to those performing PST.
- Open Access
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Metaproteomic analysis of human sonicate fluid highlights neutrophil extracellular trap formation associated with periprosthetic joint infection
Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty that can be challenging to diagnose and treat. Neutrophils are a prominent feature in PJI, with neutrophil extracellular traps (NETs) known to be present; little is known, however, about the physiology of PJI-associated NETs. Here, the proteomes of PJI and non-infectious arthroplasty failure (NIAF), analyzed using liquid chromatography tandem mass-spectrometry (LC-MS/MS) and proximity extension assay (PEA)-based profiling of fluids derived from sonication of arthroplasty components removed from patients who had undergone revision arthroplasty, were compared, with a focus on NET formation. In addition, in vitro effects of synovial fluid components on Staphylococcus aureus- induced NET formation were characterized. LC-MS/MS (PJI n = 85, NIAF n = 26) and PEA (PJI n = 95, NIAF n = 39) showed NET formation and neutrophil degranulation to be associated with PJI, with the complement cascade and platelet activation pathways identified as potential contributors. In vitro studies showed delayed NET formation in artificial synovial fluid compared to standard cell culture media conventionally used to evaluate NETs. Together, these results demonstrate the presence of NETs in PJI, identify potential pathways involved in PJI-associated NETosis, and point to an influence of synovial components on NET formation during PJI. IMPORTANCE: Periprosthetic joint infection (PJI) is a major complication of joint replacement, placing a significant burden on patients and the healthcare system. Our research reveals that neutrophils and their antimicrobial “traps” are dominant features of the immune response at the infection joint site. Importantly, we found that the unique environment of the joint delays the formation of these traps, potentially contributing to the pathogenesis of PJI. By establishing a new experimental platform tailored for the infected joint, this work provides a foundational platform for probing these mechanisms and supports the development of improved diagnostic and therapeutic strategies.
- 3 November 2026
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 14 (11)
Open AccessMetaproteomic analysis of human sonicate fluid highlights neutrophil extracellular trap formation associated with periprosthetic joint infection
Periprosthetic joint infection (PJI) is a devastating complication of total joint arthroplasty that can be challenging to diagnose and treat. Neutrophils are a prominent feature in PJI, with neutrophil extracellular traps (NETs) known to be present; little is known, however, about the physiology of PJI-associated NETs. Here, the proteomes of PJI and non-infectious arthroplasty failure (NIAF), analyzed using liquid chromatography tandem mass-spectrometry (LC-MS/MS) and proximity extension assay (PEA)-based profiling of fluids derived from sonication of arthroplasty components removed from patients who had undergone revision arthroplasty, were compared, with a focus on NET formation. In addition, in vitro effects of synovial fluid components on Staphylococcus aureus- induced NET formation were characterized. LC-MS/MS (PJI n = 85, NIAF n = 26) and PEA (PJI n = 95, NIAF n = 39) showed NET formation and neutrophil degranulation to be associated with PJI, with the complement cascade and platelet activation pathways identified as potential contributors. In vitro studies showed delayed NET formation in artificial synovial fluid compared to standard cell culture media conventionally used to evaluate NETs. Together, these results demonstrate the presence of NETs in PJI, identify potential pathways involved in PJI-associated NETosis, and point to an influence of synovial components on NET formation during PJI. IMPORTANCE: Periprosthetic joint infection (PJI) is a major complication of joint replacement, placing a significant burden on patients and the healthcare system. Our research reveals that neutrophils and their antimicrobial “traps” are dominant features of the immune response at the infection joint site. Importantly, we found that the unique environment of the joint delays the formation of these traps, potentially contributing to the pathogenesis of PJI. By establishing a new experimental platform tailored for the infected joint, this work provides a foundational platform for probing these mechanisms and supports the development of improved diagnostic and therapeutic strategies.
- Open Access
- 2 December 2025
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 75 (12)
Description of three new Dryocola species: Dryocola mayonis sp. nov., Dryocola sharpae sp. nov.and Dryocola baronae sp. nov., isolated from human clinical samples
Three previously uncharacterized bacterial species, designated strains BD586 T , BD613 T and BD626 T , isolated from human clinical specimens, were identified at Mayo Clinic, Rochester, Minnesota, USA. Initial identification efforts using matrix-assisted laser desorption ionization-time-of-flight MS and partial 16S rRNA gene sequencing proved inconclusive. Comprehensive analysis involving phenotypic characterization, biochemical assays and whole-genome sequencing was undertaken. The isolates were Gram-negative, motile, facultatively anaerobic rods, occurring singly, in pairs and in short chains; BD613 T additionally formed small aggregates. The isolates tested positive for catalase and negative for oxidase. Their colonies appeared smooth, white, opaque and non-haemolytic. Growth was observed at 35 °C under aerobic, anaerobic and CO₂-enriched conditions, as well as in media with NaCl concentrations up to 10% and at pH 7-9. Phylogenetic relationships were inferred from core gene alignments, average nucleotide identity and digital DNA–DNA hybridization comparisons. Results confirmed the placement of BD586 T , BD613 T and BD626 T within the recently established Dryocola genus, while also indicating their novelty as distinct species. The major cellular fatty acids were C 16:0 and C 17:0 cyclo. Based on these findings, a formal description of three new species, Dryocola mayonis sp. nov. (type strain BD586 T =TSD 474 T , =NCTC 15089 T , =DSM 119465 T ), Dryocola sharpae sp. nov. (type strain BD613 T =TSD 475 T , =NCTC 15090 T , =DSM 119466 T ) and Dryocola baronae sp. nov. (type strain BD626 T =TSD 476 T , =NCTC 15091 T , =DSM 119479 T ), is proposed, and the genus description of Dryocola is emended to refine its genomic, morphological and chemotaxonomic boundaries.
- 2 December 2025
- Published by Microbiology Society in International Journal of Systematic and Evolutionary Microbiology
- Vol. 75 (12)
Open AccessDescription of three new Dryocola species: Dryocola mayonis sp. nov., Dryocola sharpae sp. nov.and Dryocola baronae sp. nov., isolated from human clinical samples
Three previously uncharacterized bacterial species, designated strains BD586 T , BD613 T and BD626 T , isolated from human clinical specimens, were identified at Mayo Clinic, Rochester, Minnesota, USA. Initial identification efforts using matrix-assisted laser desorption ionization-time-of-flight MS and partial 16S rRNA gene sequencing proved inconclusive. Comprehensive analysis involving phenotypic characterization, biochemical assays and whole-genome sequencing was undertaken. The isolates were Gram-negative, motile, facultatively anaerobic rods, occurring singly, in pairs and in short chains; BD613 T additionally formed small aggregates. The isolates tested positive for catalase and negative for oxidase. Their colonies appeared smooth, white, opaque and non-haemolytic. Growth was observed at 35 °C under aerobic, anaerobic and CO₂-enriched conditions, as well as in media with NaCl concentrations up to 10% and at pH 7-9. Phylogenetic relationships were inferred from core gene alignments, average nucleotide identity and digital DNA–DNA hybridization comparisons. Results confirmed the placement of BD586 T , BD613 T and BD626 T within the recently established Dryocola genus, while also indicating their novelty as distinct species. The major cellular fatty acids were C 16:0 and C 17:0 cyclo. Based on these findings, a formal description of three new species, Dryocola mayonis sp. nov. (type strain BD586 T =TSD 474 T , =NCTC 15089 T , =DSM 119465 T ), Dryocola sharpae sp. nov. (type strain BD613 T =TSD 475 T , =NCTC 15090 T , =DSM 119466 T ) and Dryocola baronae sp. nov. (type strain BD626 T =TSD 476 T , =NCTC 15091 T , =DSM 119479 T ), is proposed, and the genus description of Dryocola is emended to refine its genomic, morphological and chemotaxonomic boundaries.
- Open Access
- 16 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5)
In Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection
Background/Objectives: Staphylococci are the most common causes of periprosthetic joint infection (PJI); new antimicrobials are needed to manage these difficult infections. Nisin A is a lantibiotic peptide derived from Lactococcus lactis that has antimicrobial activity against Gram-positive bacteria, including staphylococci, and is an FDA-approved preservative used in the food and dairy industry. Here, the in vitro nisin A susceptibility of PJI-associated staphylococci was assessed. Methods: The minimum inhibitory concentrations (MICs), minimum biofilm inhibitory concentrations (MBICs), and minimum biofilm bactericidal concentrations (MBBCs) of nisin A were measured by broth microdilution against 106 staphylococcus isolates isolated from PJI. MICs were assessed using 5 × 105 CFU/mL plus nisin A. For MBICs, biofilms were grown on pegged lids for 6 h, followed by 20 h of treatment. For MBBCs, pegged lids were transferred to plates containing media only for 20 h. The results were determined as the lowest concentrations with no visual growth. Two-dimensional MICs with nisin A and vancomycin were assessed for 20 isolates. Fractional inhibitory concentrations (FICs) were calculated to determine synergistic, additive, antagonistic, or indifferent interactions. Results: The MIC that inhibited 90% of S. aureus and S. epidermidis was 4 µg/mL, apart from for the MRSA subset (8 µg/mL). The MBIC that inhibited 90% of isolates was 4 µg/mL. The MBBCs ranged from 4 to 256 µg/mL. When tested together, nisin A and vancomycin yielded an FIC between 1.25 and 1.5, indicative of indifference, except for one isolate each of MRSA and MSSA, for which an additive effect (FIC of 1) was observed. Conclusions: Nisin A showed inhibitory activity against staphylococci that cause PJI.
- 16 May 2025
- Published by MDPI AG in Antibiotics
- Vol. 14 (5)
Open AccessIn Vitro Activity of Nisin A Against Staphylococci Isolated from Periprosthetic Joint Infection
Background/Objectives: Staphylococci are the most common causes of periprosthetic joint infection (PJI); new antimicrobials are needed to manage these difficult infections. Nisin A is a lantibiotic peptide derived from Lactococcus lactis that has antimicrobial activity against Gram-positive bacteria, including staphylococci, and is an FDA-approved preservative used in the food and dairy industry. Here, the in vitro nisin A susceptibility of PJI-associated staphylococci was assessed. Methods: The minimum inhibitory concentrations (MICs), minimum biofilm inhibitory concentrations (MBICs), and minimum biofilm bactericidal concentrations (MBBCs) of nisin A were measured by broth microdilution against 106 staphylococcus isolates isolated from PJI. MICs were assessed using 5 × 105 CFU/mL plus nisin A. For MBICs, biofilms were grown on pegged lids for 6 h, followed by 20 h of treatment. For MBBCs, pegged lids were transferred to plates containing media only for 20 h. The results were determined as the lowest concentrations with no visual growth. Two-dimensional MICs with nisin A and vancomycin were assessed for 20 isolates. Fractional inhibitory concentrations (FICs) were calculated to determine synergistic, additive, antagonistic, or indifferent interactions. Results: The MIC that inhibited 90% of S. aureus and S. epidermidis was 4 µg/mL, apart from for the MRSA subset (8 µg/mL). The MBIC that inhibited 90% of isolates was 4 µg/mL. The MBBCs ranged from 4 to 256 µg/mL. When tested together, nisin A and vancomycin yielded an FIC between 1.25 and 1.5, indicative of indifference, except for one isolate each of MRSA and MSSA, for which an additive effect (FIC of 1) was observed. Conclusions: Nisin A showed inhibitory activity against staphylococci that cause PJI.
- 24 September 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 267, 116791
Dual action electrochemical bandage operated by a programmable multimodal wearable potentiostat
- 24 September 2024
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 267, 116791
Dual action electrochemical bandage operated by a programmable multimodal wearable potentiostat